Impaired Haemostasis by Intravenous Administration of a Gelatin-based Plasma Expander in Human Subjects

Summary

The aim of this study was to investigate the effects of a gelatin-based plasma expander on blood coagulation and haemostasis in human subjects.

Six healthy men were studied in a randomised, controlled cross-over study to investigate the effects of a 60 min intravenous infusion of either 1 l gelatin-based plasma substitute (Gelofusine) or 0.9% NaCl (control). The infusion of gelatin resulted in a 1.7 fold increase in bleeding time at 60 min and a 1.4 fold increase at 120 min, while saline had no effect (p <0.05). Aggregation studies revealed a significant impairment of ristocetin-induced platelet aggregation (p <0.05), associated with a substantial decrease of vWF:ag (–32% vs. –5%, p <0.05) and ristocetin co-factor (–29% vs. +1%, p <0.05) and without in vitro impairment of the platelet glycoprotein 1b receptor. Gelatin caused a decrease in thrombin-antithrombin complexes (–45% vs. –4%, p <0.05) and F1+2 (–40% vs. +1%, p <0.05). The decrease in circulating levels of vWF:ag, vWF R:Co, thrombin-antithrombin complexes and F1+ 2 was more than could be expected by the calculated plasma-dilution generated by Gelofusine.

Our results demonstrated that the administration of a gelatin-based plasma substitute results in a significant impairment of primary haemostasis and thrombin generation. The defect in primary haemostasis appears to be related to a gelatin-induced reduction in von Willebrand factor, whereas the decreased thrombin generation may be due to the dilution of coagulation factors induced by Gelofusine.

• References

• 1 Lundsgaard-Hansen P, Tschirren B. Clinical experience with 120,000 units of modified gelatin. Dev Biol Stand 1980; 48: 251-6.
• 2 Tabuchi N, de Haan J, Gallandat Huet RCG, Boonstra PW, van Oeveren W. Gelatin use impairs platelet adhesion during cardiac surgery. Thromb Haemost 1995; 74 (06) 1447-51.
• 3 Mardel SN, Saunders F, Ollerenshaw L, Edwards C, Baddeley D. Reduced quality of in vitro clot formation with gelatin-based plasma solutions. Lancet 1996; 347: 825.
• 4 Heath ML. Clot formation and gelatin-based plasma substitutes. Lancet 1996; 347: 1336.
• 5 Baddeley DT, Saunders FM, Ollerenshaw L, Edwards CM. Clot formation and gelatin-based plasma substitutes. Lancet 1996; 347: 1763.
• 6 Mielke CH, Kaneshiro MM, Maher IA, Weiner JM, Rapaport SI. et al. The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood 1969; 34: 204-15.
• 7 Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversals. Nature 1962; 194: 927.
• 8 Cejka J. Enzyme immunoassay for factor VIII-related antigen. Clin Chem 1982; 28: 1356-8.
• 9 Weiss HJ, Hoyer LW, Rickles FR, Varma A, Rogers J. Quantitative assay of a plasma factor deficient in von Willebrand’s disease that is necessary for platelet aggregation. J Clin Invest 1973; 52: 2708-12.
• 10 Meyer D, Obert B, Pietu G, Lavergne JM, Zimmermann TS. Mulimeric structure of factor VIII/vWF in von Willebrands disease. J Lab Clin Med 1980; 95: 950.
• 11 Flordal PA. The plasma dilution factor: predicting how concentrations in plasma and serum are affected by blood volume variations and blood loss. J Lab Clin Med 1995; 126: 353-7.
• 12 Brown JE, Bosak JO. An ELISA test for the binding of von Willebrand antigen to collagen. Thromb Res 1986; 43: 303-11.
• 13 Meyer D, Girma JP. Von Willebrand factor: structure and function. Thromb Haemost 1993; 70: 99-104.
• 14 Stump DC, Strauss RG, Henriksen RA, Petersen RE, Saunders R. et al. Effects of hydroxyethyl starch on blood coagulation, particularly factor VIII. Transfusion 1985; 25: 349-54.
• 15 London MJ, Ho JS, Triedman JK, Verrier ED, Levin J, Merrick SH, Hanley FL, Browner WS, Mangano DT. et al. A randomized clinical trial of 10% pentastarch (low molecular weight hydroxyethyl starch) versus 5% albumin for plasma volume expansion after cardiac operations. J Thorac Cardiovasc Surg. 1989; 97: 785-97.
• 16 Tigchelaar I, Gallandat Huet RCG, Korsten J, Boonstra PW, van Oeveren W. Hemostatic effects of three colloid plasma substitutes for priming solution in cardiopulmonary bypass. Eur J Cardio-Thorac Surg 1997; 11: 626-32.
• 17 Mortelmans YJ, Vermaut G, Verbruggen AM, Arnout JM, Vermylen J, van Aken H, Mortelmans LA. et al. Effects of 6% hydroxytehyl starch and 3% modified fluid gelatin on intravascular volume and coagulation during intraoperative haemodilution. Anesth Analg 1995; 81: 1235-42.
• 18 Strauss RG. Volume replacement and coagulation: a comparative review. J of Cardiothorac Anaesth. 1988 (2) 6, suppl 1: 24-32.